Toronto, Canada

Grace Tharmini Tharmarajah

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Grace Tharmini Tharmarajah: Innovator in Transfection Technology

Introduction

Grace Tharmini Tharmarajah is a notable inventor based in Toronto, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of transfection reagents. Her innovative work focuses on enhancing the delivery of nucleic acids into resistant cell types, which is crucial for various therapeutic applications.

Latest Patents

Grace holds a patent for her invention titled "Compositions for transfecting resistant cell types." This patent describes a transfection reagent composition that includes 30-60 MOL. % of a cationic lipid, or a pharmaceutical acceptable salt thereof; 10-60 MOL % of a structural lipid; 10-20 MOL % of a triglyceride; and 0.1 to about 10 MOL. % of a stabilizing agent. The transfection agent is particularly effective in transfecting cells, especially neurons, with siRNA, mRNA, and plasmid nucleic acid, while maintaining the viability of the cells and the activity of the delivered nucleic acid.

Career Highlights

Throughout her career, Grace has worked with leading companies in the biotechnology sector, including Precision Nanosystems Inc. and Precision Nanosystems Ulc. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking advancements in transfection technology.

Collaborations

Grace has collaborated with talented individuals such as Anitha Thomas and Rebecca Anne Grace De Souza. These partnerships have fostered a creative environment that encourages innovation and the development of new technologies.

Conclusion

Grace Tharmini Tharmarajah is a pioneering inventor whose work in transfection technology has the potential to revolutionize the field of biotechnology. Her contributions are vital for advancing therapeutic applications and improving the delivery of nucleic acids into resistant cell types.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…